Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions reveal a strong interest in the quality and validity of clinical trial data, with comments mentioning the limited reporting and bias in safety information, such as 'clinical trials lacked proper blinding' and 'poor quality, and systematically biased.' Posts also include references to the original meta-analysis, emphasizing its significance and encouraging further review, which evidences active engagement and a focus on impact, driven by a tone of critique and caution.
Most posters acknowledge the limitations and findings of the meta-analysis, indicating moderate agreement with its conclusions.
Discussions focus heavily on the quality and implications of the research, showing high curiosity and concern about safety reporting and trial methodology.
Posts reference specific studies, criticize trial design, and suggest further reading, demonstrating deep involvement.
While some discussions highlight potential safety issues and the importance of proper adverse event reporting, the overall impact on clinical practice remains implied rather than clearly articulated.
@IntellProOrg @chemenace @lllliatttt No, it isn't. Here's peer-reviewed proof of it. "Available toxicity information from clinical trials of finasteride in men with AGA is very limited, is of poor quality, and seems to be systematically biased." https://t.co/6uS5MKWUXV
2. Belknap SM et al. Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis. JAMA Dermatol. 2015 Jun;151(6):600-6. doi: 10.1001/jamadermatol.2015.36. https://t.co/jEF4KnQCuc
@HairDAO_ @AbudBakri you should send him this video https://t.co/qe66mSFEji
RT @FinasterideInfo: 2. Belknap SM et al. Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysi…
For an in-depth review of clinical trials of finasteride for hair loss, see: Belknap SM, et al. Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis. JAMA Dermatol. 2015. https://t.co/KigTwrqiCy https://t.co/jEF4KnQCuc 3/
@Putnam_Cole @LoyolaUrology Belknap SM et al. Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis. JAMA Dermatol. 2015;151(6):600-606. https://t.co/KigTwrqiCy https://t.co/jEF4KnQCuc
Male androgenetic alopecia affects up to 60% of men by age 50, with treatments like finasteride and minoxidil. Finasteride is highly effective but concerns over side effects impact its use; minoxidil is safer but less…
This video discusses the potential health risks associated with long-term use of finasteride and dutasteride, including serious issues like fatty liver, insulin resistance, and kidney problems. It emphasizes the…
@broden3749 @AlphaGels @Prohypnogamer @slitherwinglove Clinical trials lacked proper blinding, was limited to short durations, did not differentiate between mild and severe sexual dysfunction, did not screen patients after stopping the drug. https://t.co/6uS5MKWUXV
@HairDAO_ @AbudBakri you should send him this video https://t.co/qe66mSFEji
@IntellProOrg @chemenace @lllliatttt No, it isn't. Here's peer-reviewed proof of it. "Available toxicity information from clinical trials of finasteride in men with AGA is very limited, is of poor quality, and seems to be systematically biased." https://t.co/6uS5MKWUXV
@BigFoot_RL @bryan_johnson @xtbot Data did not test for severity or persistency. https://t.co/6uS5MKWUXV https://t.co/Kqigzm8OyU
For an in-depth review of clinical trials of finasteride for hair loss, see: Belknap SM, et al. Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis. JAMA Dermatol. 2015. https://t.co/KigTwrqiCy https://t.co/jEF4KnQCuc 3/
@Putnam_Cole @LoyolaUrology Belknap SM et al. Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis. JAMA Dermatol. 2015;151(6):600-606. https://t.co/KigTwrqiCy https://t.co/jEF4KnQCuc
Belknap SM et al. Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis. JAMA Dermatol. 2015 Jun. doi: 10.1001/jamadermatol.2015.36. https://t.co/jEF4KnQCuc
@Rashid_Dahabreh @Dr_3ebsh Is that 1% number from clinical trials? The clinical trials were later found to have inadequate safety reporting. Belknap SM et al. Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis. JAMA Dermatol. https://t.co/jEF4KnQCuc
RT @FinasterideInfo: 2. Belknap SM et al. Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysi…
2. Belknap SM et al. Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis. JAMA Dermatol. 2015 Jun;151(6):600-6. doi: 10.1001/jamadermatol.2015.36. https://t.co/jEF4KnQCuc
RP
FW
PW